Our Partnership With Photonamic GmbH & Co. KG

In 2018, NX Development Corp became a subsidiary of Photonamic GmbH & Co. KG, a global leader in developing fluorescence-based diagnostic and therapeutic technologies.

This partnership has strengthened our position in the market and enabled us to expand the reach of Gleolan™ further.

Collaboration With Medexus Pharma

In March 2022, we entered into a partnership agreement with Medexus Pharma to commercialize Gleolan™ in the United States.

This collaboration aims to make our innovative brain tumor visualization technology more accessible to patients and surgeons across the region.

Research and Publications: Advancing the Field of Neurosurgery

At NX Development Corp, we are dedicated to advancing the knowledge and understanding of brain tumor visualization.

Our research and publications showcase our commitment to improving outcomes for cancer patients and their surgeons through the use of Gleolan™.